Why a Daily Semaglutide Injection Is Not How This Medicine Works

The myth worth correcting first: why 'daily' and 'semaglutide injection' got mixed up

The confusion is understandable. People searching for a daily semaglutide injection are often thinking of GLP-1 medicines as a broad category, and liraglutide (Saxenda), an older GLP-1 injection for weight management, is taken daily. Semaglutide was specifically engineered to last a full week in the body. Its half-life of roughly seven days means the medicine's concentration stays high enough throughout the week to suppress appetite and slow gastric emptying without a top-up. Once-weekly dosing is not a convenience shortcut; it reflects the molecule's pharmacology.

There is also a genuinely different semaglutide product that is taken daily: the oral Wegovy tablet, approved by the MHRA on 11 June 2026 as the first oral GLP-1 medicine licensed for weight management in the UK. Taken first thing in the morning before food, it dissolves with the help of an absorption enhancer (SNAC). The tablet's daily schedule is specific to the oral formulation only. For more on how the two formats compare, the non-injection semaglutide page covers the distinction in full. The injection and the tablet are separate licensed products, and switching between them requires a prescriber's assessment, not just a swap.

You can also read the NHS's own medicines page for semaglutide, which sets out the licensed dosing schedules in plain language and is one of the clearest public-facing sources available.

What the weekly injection schedule looks like from week one

For the Wegovy injection, the titration ladder matters more than any single week's dose. Treatment opens at 0.25 mg, a level chosen to let the body adjust rather than to produce significant weight loss straight away. The dose steps up roughly every four weeks (through 0.5 mg, 1.0 mg and 1.7 mg) before reaching the 2.4 mg maintenance dose. Some people tolerate each step easily; others feel nauseous enough to extend a rung before moving on. That pacing decision sits with the prescriber, not with the patient alone.

Practically speaking, many people find that picking the same day each week and pairing it with an existing habit (a Saturday morning, say, or the evening after a particular regular activity) makes the routine stick. The pen itself is kept in the fridge door. After the injection it can sit at room temperature briefly, but for the exact window the Patient Information Leaflet is the definitive source, and that is deliberately where we leave it. Injection sites rotate between the abdomen, thigh and upper arm to avoid irritation.

For a broader look at how the injectable semaglutide works across the full programme, including what the weekly rhythm feels like month to month, that page gives a thorough account. The question of whether it is daily or weekly also comes up often enough that we have a dedicated answer on the Wegovy daily or weekly injection page if you want the short version.

Side effects: what happens between weekly doses

A common worry with a once-weekly medicine is whether side effects spread across the whole week. In practice, the gastrointestinal effects most people notice (nausea, loose stools, reflux, occasional vomiting) tend to cluster in the first day or two after an injection, particularly after a dose increase, and then settle before the next week's jab. They are the body responding to the slower gastric emptying that makes the medicine effective.

Staying well-hydrated and eating smaller, lower-fat meals on injection day reduces the intensity for most people. Persistent or severe symptoms that do not ease within a few days are worth raising with a prescriber rather than pushing through. The MHRA's Yellow Card scheme allows patients to report any suspected side effects directly, which is worth knowing about. Separately, anyone who develops severe stomach pain (particularly pain that spreads to the back) should seek urgent medical advice, as this can be a sign of pancreatitis, a known but uncommon risk flagged in the UK safety guidance for GLP-1 medicines.

People using oral contraceptives alongside tirzepatide (a different GLP-1 medicine) need additional contraceptive cover during dose changes; the published evidence for semaglutide does not show the same interaction, but the contraception question is one to raise with your prescriber at any consultation. For a fuller safety picture of the semaglutide injection, that page covers contraindications and monitoring in more depth.

Checking whether the once-weekly injection suits your situation

The Wegovy injection is licensed for adults with a BMI of 30 or above, or 27 or above if at least one weight-related health condition is present, such as high blood pressure, high cholesterol, obstructive sleep apnoea or type 2 diabetes. Lower thresholds apply for some ethnic backgrounds under UK guidance. BMI alone does not confirm suitability; the prescriber looks at the full clinical picture, including other medicines you take, relevant medical history, and whether you have tried other approaches. NICE's appraisal of semaglutide (TA875) sets out the criteria for NHS-funded access through specialist services, which differ from the private licensed eligibility criteria.

If the injection route feels daunting or you prefer not to inject at all, oral options exist. The semaglutide injections overview can help clarify how the injection compares to other formats before you decide. For a wider look at what other treatments are available (including how costs stack up across different options) the Wegovy prices page gives honest market context. Full information on all the weight-loss treatment options we can review sits in one place if you want to compare before starting.

A real prescriber reads every consultation, not automated software. Speak to our prescribers if you want a clinical assessment of whether the once-weekly semaglutide injection is right for you, or whether another route makes more sense for your circumstances. Start at our free consultation page.